DMRA · Damora Therapeutics Inc
United States · RS rating 17 · As of 2026-10-14
| Price | 18.43 USD |
|---|---|
| 1-day change | -0.7% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 8 / 8 / 88 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 37 / 26 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +37.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +46.0% |
| Market cap (USD) | $1.5B |